ArticleObstetrics and gynecology2026
Contribution of Comorbidities and Pregnancy Complications to Severe Maternal Morbidity in the United States.
Article in Obstetrics and gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo quantify the extent to which rising rates of severe maternal morbidity (SMM) in the United States from 2016 to 2022 are attributable to increasing prevalence of maternal risk factors, including advanced maternal age, obesity, pregestational diabetes mellitus, gestational diabetes, chronic hypertension, and hypertensive disorders of pregnancy (HDP).
methodsWe conducted a retrospective cohort study using the Nationwide Readmissions Database from 2016 to 2022, representing more than 25 million weighted delivery hospitalizations. The primary outcome of SMM was identified with the Centers for Disease Control and Prevention's 21-condition algorithm; a secondary outcome excluded transfusion to improve specificity. Temporal trends in SMM and maternal risk factors were assessed with the Cochran-Armitage test. To quantify the contribution of changes in risk factor prevalence to the overall increase in SMM, we applied a parametric g-computation-based decomposition comparing standardized risks in 2016 and 2022, including counterfactual scenarios in which the distribution of each risk factor was held at 2016 levels.
resultsBetween 2016 and 2022, the prevalence of SMM increased from 1.5% to 2.2%, and nontransfusion SMM rose from 0.7% to 1.0% (both P <.001). The prevalence of HDP rose from 9.8% to 16.6%, chronic hypertension from 1.4% to 2.6%, and obesity from 9.7% to 15.4%. All maternal risk factors were independently associated with higher odds of SMM. Decomposition analysis showed that HDP accounted for 32.4% (95% CI, 31.2-33.7%) of the increase in SMM and 51.3% (95% CI, 48.5-54.9%) of the increase in nontransfusion SMM. Chronic hypertension and obesity also contributed meaningfully, whereas advanced maternal age and gestational diabetes accounted for a smaller share of the increase.
conclusionThe rise in SMM in the United States is partially attributable to the growing burden of chronic hypertension, HDP, and obesity. These findings highlight the urgent need for preventive interventions targeting cardiometabolic health before, during, and after pregnancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.